The company hopes to accrue around 5,000 patients over the next few years, creating a broad dataset coupling outcomes with comprehensive DNA, RNA, and protein analyses.
The new data supports the continued marketing of BioNTech's breast cancer subtyping assay as an alternative to IHC, and suggests added value for the test in assessing Ki-67 specifically.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
Eleven new recommendations were issued to address appropriate HER2 testing and clinical guidance in individuals with advanced gastroesophageal adenocarcinoma.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.
The molecular analysis firm saw instrument sales rise 62 percent, and announced plans for a new digital spatial profiling instrument.
The test may help identify patients most likely to respond to Roche's new metastatic urothelial cancer drug Tecentriq, the FDA said.
The test, which relies on multiplex IHC and imaging to calculate a PD-1/PD-L1 interaction score, predicted response in melanoma patients better than PD-L1 testing alone.
The test, when used as intended, allows doctors to gauge the magnitude of benefit melanoma patients might derive from the immunotherapeutic Opdivo.
Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.
People around the globe took to the streets to support science — some with signs.
Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.
In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.